Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Advisory Committee Conflict Policy Takes A Toll; Chairs Plan Response

Executive Summary

Cardiovascular & Renal Drugs Advisory Committee Chair William Hiatt plans to write an editorial concerning the need for a more transparent conflict of interest policy for panel members

You may also be interested in...



Advisory Panel Conflict Waivers To Stay; FDA Will Provide Clarity On Process

FDA's plan for improving its advisory committee member selection process focuses on increasing the transparency and consistency of the existing process rather than an overhaul of its practices

Hypertension Class Labeling Does Not Release Sponsors From Large Trials

FDA should ensure that manufacturers do not construe the addition of outcomes claims to antihypertensive drug labels as lowering the approval standards for future hypertension agents, members of FDA's Cardiovascular & Renal Drugs Advisory Committee emphasized during an April 26 meeting

Hypertension Class Labeling Does Not Release Sponsors From Large Trials

FDA should ensure that manufacturers do not construe the addition of outcomes claims to antihypertensive drug labels as lowering the approval standards for future hypertension agents, members of FDA's Cardiovascular & Renal Drugs Advisory Committee emphasized during an April 26 meeting

Related Content

UsernamePublicRestriction

Register

ID1131849

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel